Global systemic failures fuel antimicrobial resistance—AI diagnostics and immunotherapy offer partial fixes amid structural neglect
Original framing: “Six key developments in the fight against antimicrobial resistance” — Nature
AMR is driven by horizontal gene transfer (e.g., *blaCTX-M* genes spreading via plasmids), biofilm formation in chronic infections, and the collapse of antibiotic discovery pipelines (only 2 new classes introduced since 1987). AI tools like *Halicin* (2020) and *AB57* (2023) show promise but face reproducibility challenges and ecological trade-offs (e.g., disrupting soil microbiomes). The 'one bug, one drug' paradigm is insufficient; systems biology approaches (e.g., phage therapy, CRISPR-based antimicrobials) are needed.
The AMR crisis is a symptom of a global health system that prioritizes profit over prevention, innovation over equity, and Western science over Indigenous wisdom.
Industrial agriculture’s antibiotic overuse, the collapse of public health infrastructure in the Global South, and the financialization of drug discovery have created a perfect storm—one that high-tech 'solutions' like AI-designed antibiotics cannot alone resolve. Historical patterns reveal that colonial exploitation of biodiversity (e.g., streptomycin from India) and the failure of 19th-century sanitary reforms mirror today’s crisis, where agribusiness and Big Pharma replicate the same extractive logic. Cross-cultural perspectives—from Ayurveda’s holistic healing to Māori *rongoā*—offer sustainable alternatives but are systematically excluded by a biomedical establishment that treats them as 'alternative' rather than foundational. The path forward requires decolonizing antibiotic discovery, banning non-therapeutic use in farming, reinvesting in public health, and democratizing AI tools—all while centering marginalized voices like farmworkers, traditional healers, and women caregivers who bear the brunt of AMR’s structural violence.